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Abstract
T cell-dependent development of anti-factor VIII (FVIII) antibodies that neutralize FVIII activity
is a major obstacle to replacement therapy in hemophilia A. To create a less immunogenic
therapeutic protein, recombinant FVIII can be modified to reduce HLA binding of epitopes based
on predicted anchoring residues. Here, we used immunoinformatics tools to identify C2 domain
HLA DR epitopes and predict site-specific mutations that reduce immunogenicity. Epitope
peptides corresponding to original and modified sequences were validated in HLA binding assays
and in immunizations of hemophilic E16 mice, DR3 and DR4 mice and DR3xE16 mice.
Consistent with immunoinformatics predictions, original epitopes are immunogenic.
Immunization with selected modified sequences lowered immunogenicity for particular peptides
and revealed residual immunogenicity of incompletely de-immunized modified peptides. The
stepwise approach to reduce protein immunogenicity by epitope modification illustrated here is
being used to design and produce a functional full-length modified FVIII for clinical use.
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1. Introduction
Hemophilia A, an X-linked recessive genetic bleeding disorder caused by mutations of
coagulation factor VIII (FVIII), is the most common type of bleeding disorder with a
prevalence of 1 in 5000–10000 live male births. FVIII is a protein that has a six-domain
structure, A1-A2-B-A3-C1-C2. The full-length gene product is processed intracellularly into
a heavy chain and light chain in connection with a divalent metal ion. The heavy chain of
FVIII contains the A1, A2 and a residual part of the B domain; whereas the light chain
contains A3, C1 and C2 domains [1]. Previous studies have shown that sites in the A1, A2,
A3 and C2 domains of FVIII are involved in its pro-coagulant interactions [2–4] which lead
to the activation of Factor IX in the “intrinsic” coagulation pathway, thrombin activation and
fibrin formation. Hence, mutations in FVIII lead to excessive bleeding and can be life-
threatening.
Current treatment for hemophilia A consists of repeated intravenous administration of
plasma-derived FVIII or recombinant FVIII [5]. However the development of anti-FVIII
antibodies that neutralize FVIII activity (called “inhibitors”) is a major obstacle to continued
FVIII replacement therapy. Up to 30% of all hemophiliacs develop inhibitors during the
course of treatment. Nearly 50% of severe hemophiliacs, who have major deletions in the
FVIII gene, develop inhibitors because they have no detectable FVIII activity or circulating
FVIII protein [6, 7].
Inhibitor development has been shown to be a T cell dependent process in both animal
studies and clinical evidence from hemophiliac AIDS patients [8–13]. This process is
dependent on antigen presenting cell (APC) signaling to CD4+ T helper cells [9, 11–13].
Disruption of CD40/CD40L interactions by MR1, an anti-CD40L antibody, completely
prevented inhibitor formation and both Th1 and Th2 responses in hemophilic mice after
FVIII treatment [10]. T cell epitopes in FVIII have been identified that appear to play a
pivotal role in this T cell-dependent immune response to FVIII [14]. In the present study, we
focused on T cell epitopes in the C2 domain because it has been reported that this domain
contains many B cell epitopes [15]. In addition, T cell epitopes have been mapped to C2
domain residues 2181–2312, [16, 17] 2191–2210, 2241–2290, and 2291–2330 [15, 18].
Some of these T cell epitopes overlap with inhibitory antibody binding sites [15, 18–20].
Because the immunogenicity of FVIII [21] and lack of tolerance to the non-native protein in
hemophilia patients both contribute to inhibitor formation, the therapeutic efficacy of FVIII
can be limited [5, 22–25]. Methods that successfully reduce the immunogenicity of FVIII
would improve quality of life and reduce treatment-associated costs for individuals affected
by inhibitors. A number of approaches to induce FVIII tolerance are used in the clinic but
have significant limitations [26–28]. Recent studies demonstrate a role for regulatory T cells
in controlling antibody responses, including antibodies against FVIII, and offer new
immunomodulatory approaches to preventing inhibitor formation [29–31]. Here, we report a
novel method to develop a modified version of FVIII by T cell epitope modifications
designed to reduce binding of FVIII epitopes to MHCII, leading to a reduction or failure of
this antigen being presented to T cells, while preserving the function of FVIII. This process
is called de-immunization for functional therapeutics or “DeFT” [32, 33].
An early application of de-immunization by T cell epitope modification came from alanine
substitutions to the MHC II anchoring residues Y73, K74, R77, E80, and D82 of
Staphylokinase, individually or in combination. Warmerdam et al. showed that mutations to
alanine reduced or eliminated T cell response and clinical immunogenicity of
Staphylokinase [34], presumably due to reduction in HLA binding affinity.
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We employed a stepwise process to identify and de-immunize FVIII C2 epitopes: 1) in silico
epitope mapping, 2) validation of computational predictions in vitro and in vivo, 3) selection
of epitopes to modify, 4) iterative in silico modification and analysis accounting for
potential immunogenicity and conservation and 5) validation of carefully selected modified
sequences in vitro and in vivo.
In previous studies, we found that predicted epitope peptides in the C2 domain of FVIII
could be modified to reduce MHC II binding, leading to reduced immune recall
(antigenicity) in vitro in FVIII KO mice (E16, H-2b) immunized with FVIII [35]. In the
current study, we have confirmed and extended these studies to humanized HLA-DR
transgenic mice, using state-of-the art immunoinformatics tools to select and de-immunize
the immunodominant epitopes. We provide evidence that the approach can be used to design
de-immunized peptides that are less likely to cause de novo immunogenic responses. The
algorithms EpiMatrix and ClustiMer were used to select promiscuous T cell epitopes that
would bind to multiple human MHC II alleles [36]. OptiMatrix was used to iteratively
analyze anchor residue substitutions so as to identify modifications that would interfere with
MHC binding while accounting for naturally conserved substitutions [33]. Peptides
representing the original predicted epitopes (ORG) and their OptiMatrix-defined
modifications (MOD) were then evaluated in an HLA binding assay. Finally, the peptides
(or FVIII) were used to immunize mice so as to measure their potential for immune recall
(antigenicity) and de novo (immunogenicity) responses. We found that 6 ORG peptides
(2191-O, 2231-O, 2254-O, 2271-O, 2299-O and 2310-O) were immunogenic in DR3
transgenic mice, in DR4 mice and in DR3 mice crossed to FVIII knockout (KO) hemophilic
mice (DR3×E16). After identification of ORG peptides, the MODs were tested in de novo
immunogenicity studies. We successfully identified several MODs that were non-
immunogenic in our mouse models, although selected MOD peptides retained
immunogenicity following immunization of mice with the peptides. This stepwise approach
using immunoinformatics tools followed by in vitro and in vivo validation may be of use to
develop novel FVIII therapies and for the development of less immunogenic bio-
therapeutics.
2. Materials and Methods
2.1 Tools for de-immunization: the EpiMatrix system
The EpiMatrix computational epitope mapping method has been published [36, 37]. Briefly,
the sequence of human FVIII C2 domain was parsed into overlapping 9-mer frames and the
immunogenic potential of each frame was assessed against a panel of eight archetypal HLA
class II alleles (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801,
DRB1*1101, DRB1*1301 and DRB1*1501) that represent >90% of MHC diversity in the
human population [38]. A ‘Z’ score for each analyzed 9-mer is assigned by EpiMatrix. Any
peptide scoring above 1.64 on the EpiMatrix ‘Z’ scale (approximately the top 5% of the
random peptide set) has a significant chance of binding to the MHCII molecule and is
known as a ‘hit.’ Peptides scoring above 2.32 on the scale (the top 1%) are extremely likely
to bind; most published T cell epitopes fall within this range of scores. These EpiMatrix
results were then screened for the presence of T cell epitope clusters with ClustiMer.
Regions of high immunogenic potential, defined as having a score above 10 on our
immunogenicity scale, were designated “original” (ORG) peptides and verified by in vitro
methods [39].
Next, to identify amino acids within the identified immunodominant epitope regions (ORG)
that were suitable for modification, we evaluated the contribution of each amino acid in
these regions to HLA binding using OptiMatrix (part of the EpiVax tool kit for de-
immunization). OptiMatrix begins with looking at “critical” residues, which contribute most
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to MHC binding affinity across multiple 9-mer frames and multiple HLA alleles, and
averages the contribution of each amino acid to binding across 9-mer binding frames and
HLA alleles. The program then iteratively substitutes all 19 alternative amino acids in any
given position of a protein sequence (with operator-defined input that may limit the list to
naturally conserved variants) and then reanalyzes the predicted immunogenicity of the
sequence, following that change. The predicted disruptive impact on the overall
immunogenic potential of the MOD peptides was verified by in vitro methods as well.
2.2 Synthetic peptides
Original (ORG) and modified (MOD) peptides corresponding to the epitope selections were
synthesized (New England Peptide, Gardner, MA, USA) by 9-fluoronylmethoxy-carbonyl
(Fmoc) method on an automated Rainen Symphony/Protein Technologies synthesizer. We
only used peptides that were purified to 80% or higher by HPLC, as these give more
accurate results.
2.3 HLA binding assay
Class II HLA binding assays were used to estimate the affinity of predicted epitope
sequences for multiple HLA alleles. We employed a competition-based HLA binding assay
initially described by Steere et al [40]. and adapted for higher throughput by EpiVax. In 96-
well plates, non-biotinylated test peptides at 100 μM competed for binding to purified Class
II molecules (50 nM) against a biotinylated standard peptide at a fixed concentration (0.1
μM) for 24 hours at 37°C to reach equilibrium. Class II complexes were then captured on
ELISA plates using pan anti-Class II antibodies (L243, anti-HLA-DR). Plates were washed
and incubated with Europium-labeled Streptavidin for 1 hour at room temperature. The
Europium activation buffer was added to develop the plates for 15–20 minutes at room
temperature before they were read on a Time Resolved Fluorescence (TRF) plate reader. All
assays were performed in triplicate. Binding assays were performed for 5 alleles:
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701 and DRB1*1501, which provided a
broad representation of class II HLA allele binding pockets [38].
2.4 Mice
The hemophilic FVIII KO mouse strain (E16) has been characterized previously [41, 42].
Hemizygous adult male and homozygous female E16 mice, aged 6–10 weeks, were used in
this study. These mice, on a C57Bl/6 background, have murine MHCII molecules (H-2b).
HLA class II (HLA-DR) transgenic mice expressing HLA-DR4 (DRB1*0401) were
obtained from Taconic Farms. HLA-DR3 (DRB1*0301) mice were provided by EpiVax;
these mice were originally obtained from Dr. Chella David (Mayo Clinic, Rochester, MN)
under commercial license. Previous studies have shown that expression of HLA-DR
molecules in these mice is comparable with regular murine MHCII molecules. However, it
should be noted that these mice completely lack all endogenous murine MHCII genes, so
that the T cell responses are restricted by the transgenic HLA-DR [43, 44]. Hemophilic DR3
(DR3×E16) mice were generated by the crossing of E16 mice to DR3 mice and typed for
expression of MHCII and FVIII mutation. Female F1, DR3+/H-2b+/FVIII−/−, were used in
this study after genotyping. All animals were housed and bred in pathogen-free micro
isolator cages at the animal facilities operated by the University of Maryland School of
Medicine, and animal protocols were approved by the Institutional Animal Care and Use
Committee of the University of Maryland, School of Medicine. The genotypes of
hemophilic mice were confirmed by polymerase chain reaction (PCR) analysis of genomic
DNA extracted from tail samples.
Moise et al. Page 4
Clin Immunol. Author manuscript; available in PMC 2013 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.5 Mouse immunizations
Groups of mice were immunized with either rFVIII or 50 μl indicated peptides, 3 μg each,
emulsi ed in CFA (Sigma, St. Louis, MO) per injection site via the foot pad and the base of
tail. Draining LNs (superficial inguinal and popliteal) were removed 14 days post
immunization, and the dissociated cells were washed and cultured in 96-well microculture
plates (0.5×106 cells per well) in complete RPMI 1640 (supplemented with 1mM sodium
pyruvate, 100 mg/ml penicillin and streptomycin, 2mM glutamine, 50 μM 2-
mercaptoethanol, 20 mM HEPES, 1× nonessential amino acids, 2.0% FBS and 0.5%
hemophilic mouse serum). 2–3 mice were used per group and experiments repeated 3–4
times with reproducible results.
2.6 T cell Proliferation Assay
Thymidine incorporation and T cell proliferation assays were performed at University of
Maryland, as previously described [45]. Briefly, pooled LN cells from each group were
cultured in 96-well plates (0.5×106 cells per well) with dilutions of antigen (3-fold dilutions
ranging 0.1–10 μg/ml) for 48 hours in RPMI 1640 with 2% FBS and 0.5% hemophilic
mouse serum. After 48 hours, cultures were pulsed with 1 μCi/well of [3H]-methyl-
thymidine (Amersham Life Sciences, Arlington Heights, IL) and incubated for another 16–
20 hours. Cells were then harvested on glass fiber filters. Incorporation of thymidine was
measured by a beta counter (MicroBeta TriLux; PerkinElmer Life and Analytical Sciences,
Waltham, MA). Values were expressed in counts per minute (CPM) with antigens
(peptides). Each sample was run in triplicate or quadruplicate. The mean CPM from each of
the wells were calculated and the background subtracted for statistical calculations, and
expressed as delta CPM (Δ CPM). Background levels (i.e., CPM without antigen) were
typically less than 6000 CPM. Each Δ CPM point is the mean ± SEM of triplicate or
quadruplicate cultures.
2.7 Statistical analysis
Statistical differences were determined using a two-tailed unpaired Student’s t-test. A p
value < 0.05 was considered to be statistically significant.
3. Results
3.1 Six high HLA binding epitope peptides identified in C2 domain of FVIII
To identify immunogenic “clusters” in T cell epitope regions of FVIII’s C2 domain, we
utilized the EpiMatrix and ClustiMer algorithms. The 9-mer epitopes and epitope clusters
for eight prevalent HLA class II alleles are shown in Figure. 1. We identified six epitope
clusters at amino acid positions 2191–2210, 2231–2251, 2254–2269, 2271–2289, 2299–
2317 and 2310–2330. Their corresponding cluster scores are 4.15, 10.69, 5.62, 10.17, 12.92
and 20.86, respectively. All six clusters overlap with published FVIII epitopes as shown in
Figure 1 [46, 47] although the in silico tools provided a detailed analysis that more finely
maps the epitopes in this FVIII domain.
3.2 Epitope modification lowers HLA binding
We used OptiMatrix to identify and evaluate the contribution of critical HLA binding amino
acid residues in the most immunogenic regions of the FVIII C2 domain. These amino acids
were substituted with residues predicted to have a disruptive impact on HLA binding. To
minimize perturbations to protein structure and function, substitutions were crafted with the
aim of reducing the propensity of the peptide to bind to MHC while using the minimal
number of substitutions. Several alternative modifications (MODs) were prepared for each
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epitope ranging from one to three mutations; their nomenclature reflects the increasing
severity of the mutations (M1–4) (Table 1).
Next, we assessed the effects of the modifications by comparing the HLA binding capacity
of original (ORG) and MOD peptides in a binding assay screen. Peptide binding to
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, and DRB1*1501 was evaluated. As
shown in Fig. 2, at a concentration of 100 μM, 2191-O bound strongest, as an average across
HLA alleles, and 2231-O weakest among the ORG peptides. 2231-O inhibited competitor
binding by an average of only 20%. Lower than predicted HLA interactions may be
explained by peptide aggregation or folding that interferes in the binding assay. As
predicted, most of the peptide modifications lowered the average binding over the array of
HLA alleles tested with the single exception of 2231 MODs. As the 2231-O peptide did not
bind well to begin with, modifications to 2231-O did not significantly reduce binding.
It is perhaps not surprising that the different modifications had a variable effect on average
HLA binding, and increasing the number of substitutions decreased the propensity of the
peptide to bind. For example, 2191-M2, containing two substitutions, significantly reduced
binding whereas the corresponding 2191-M1, containing only one, only moderately reduced
binding (Fig. 2).
3.3 De novo immunogenicity of computationally predicted FVIII T-cell epitopes
To initially evaluate the immunodominant peptides predicted by our programs, E16 and DR
transgenic mice were immunized with FVIII and then their LN cells stimulated in vitro with
the identified ORG peptides in C2. Our results verified that FVIII could be processed to
present the ORG peptides to the immune system of these mice to various degrees dependent
on the MHC type of the host (data not shown); i.e. the peptides stimulated recall immune
responses, indicating that the sequences are antigenic.
Next, to validate the de novo immunogenicity of ORG sequences, E16 and DR transgenic
mice were immunized with all six ORG peptides and the ensuing immune response to the
peptides evaluated in T cell proliferation assays using lymph node cells. As shown in Fig.
3A, only 2191-O stimulated proliferative responses in E16 mice. 2271-O had the highest
response in DR3 mice (Fig. 3B). Further evidence of this selective immunodominance is
revealed in DR3×E16 mice as T cell proliferation responses to both 2191-O and 2271-O
peptides depended on the expression of H-2b as well as DR3 in the mice (Fig. 3C). Note that
the response to 2271-O was independent of whether the DR3 mice were on a hemophilic
background, suggesting that dissimilarity between the human FVIII epitope and the murine
FVIII epitope may be a key driver of the immune response for this HLA allele. Indeed, there
is a non-conservative sequence mismatch between mouse and human FVIII in a predicted
DR3 epitope in 2271-O that could explain the immunogenicity of this peptide (Table 2). In
DR4 mice, peptides 2231-O and 2310-O showed the highest responses (Fig. 3D). These four
immunodominant epitopes (2191-O, 2271-O, 2231-O, 2310-O) were selected as candidates
to study how modifications impact recall immune responses in mice immunized with ORG
peptides (antigenicity) and de novo immune responses in mice exposed to MOD peptides
(immunogenicity).
To further understand these results, we explored the possibility that immunodominance
observed in vivo was a function of peptide competition for MHC binding. 2191-O, which is
immunodominant in E16 mice, was used to test this hypothesis. E16 mice were immunized
with (i) 2191-O alone, (ii) a pool of ORG peptides including 2191-O or (iii) OVA with
2191-O. 2191-O-specific responses were then evaluated by proliferation assay in the
presence of competitor peptide or OVA (Appendix, Figure 1). We found that 2191-O
stimulated similar dose-dependent proliferation levels no matter whether mice were
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immunized with 2191-O alone (Appendix, Figure 1A) or with a pool of ORG peptides
(Appendix, Figure 1B). Moreover, proliferation was not affected by the presence of
competitor ORG peptides over a range of concentrations. E16 mice co-immunized with
2191-O and OVA mounted an immune response against both immunogens (Appendix,
Figure 1C). Taken together, these results suggest that there was no competition among ORG
peptides and presentation of different ORG peptides to T cells corresponded to their
respective MHC binding affinities.
3.4 Modifications of immunodominant peptides lower their antigenicity and
immunogenicity
To investigate the effects of epitope modification on the antigenicity and immunogenicity of
immunodominant peptides, DR3×E16 mice and DR4 mice were immunized with either the
ORG immunodominant peptides or the corresponding MOD epitopes. These studies were
undertaken in consideration of the potential applications of de-immunized FVIII. Recall
immune responses (antigenicity) measured in MOD peptide stimulations of LN cells taken
from ORG peptide-immunized mice would correspond to the T cell response to de-
immunized FVIII in hemophiliacs previously treated with wild type FVIII. De novo immune
responses (immunogenicity) to MOD peptides in stimulations of LN cells taken from MOD
peptide-immunized mice would represent the T cell response to de-immunized FVIII in
FVIII-naïve hemophiliacs.
DR3×E16 mice immunized with 2191-O peptide, the H-2b dominant sequence, showed
lower recall responses with 2191-M2 but not 2191-M1, indicating the importance of the
F2200G mutation for diminished antigenicity (Fig. 4A, Table 1). Notably, the nearly
identical response observed for 2191-O and 2191-M1 suggests that the F2196G mutation of
2191-M1 alone would not be sufficient to de-immunize this epitope in FVIII. Additional
mutations would be required such as F2200G, which lowered antigenicity as shown for
2191-M2 (Figure 4A). Although this epitope is dominant in the context of mouse MHC, and
not for the HLA alleles tested here, this result illustrates an important de-immunization
principle: ORG-reactive T cells that may be present in FVIII-treated hemophiliacs could still
produce undesired immune responses to a de-immunized FVIII bearing motifs for particular
HLA alleles. Careful selection of modifications and testing of each of the MODs for
potential immunogenicity, as done in this stepwise approach, would be necessary to produce
an effectively de-immunized FVIII.
In DR3×E16 mice immunized with 2271-O peptide, the DR3 immunodominant epitope, all
modifications lowered antigenicity in direct proportion to the number of strong anchor
substitutions (Fig. 4B, Table 1). In DR4 mice immunized with 2231-O, 2231-M1 and -M2
showed the lowest antigenicity (Fig. 4C). The F2234G mutation present in 2231-M1 appears
to be sufficient to reduce antigenicity as Q2246T does not further diminish the cellular
response to 2231-M2 (Table 1).
We also found that in DR4 mice immunized with 2310-O, all modifications lowered
antigenicity. While the W2313S mutation reduced proliferation only at the highest peptide
concentration tested for 2310-O, the additional mutation L2319G and M2321S (M2) or
L2324G (M2) reduced antigenicity with dose dependency (Fig. 4D and Table 1).
To measure immunogenicity of modified epitopes, DR3×E16 mice were immunized with
either a mixture of 2191 (2191-M1, -M2) or 2271 MODs (2271-M1, -M2, -M3). We found
that 2191-M2 was less immunogenic than 2191-M1; this was similar to the antigenicity
results in 2191-O immunized mice (Fig. 5A). Notably, 2191-M1 was as immunogenic under
these conditions as the 2191-O peptide. One explanation for the similarity may be that 2191-
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M1-reactive T cells cross-react with 2191-O, although this type of assay is not designed to
test T cell cross-reactivity.
In DR3×E16 mice immunized with a mixture of 2271 MODs (2271-M1, -M2, M3), 2271-
M3 was less immunogenic than the other MODs (Fig. 5B) as was observed in the
antigenicity study. Notably, 2271-O cross-reacted to a lesser extent with MOD-reactive T
cells than did 2291-O to T cells raised in response to immunization with its own MODs.
Additionally, in DR4 mice immunized with a mixture of 2231 MODs (2231-M1, -M2, -M3),
we found that 2231-M1 was less immunogenic than 2231-O and the other MODs of 2231
(Fig. 5C). 2310-M2 was less immunogenic, even at a high concentration in vitro, compared
with the other MODs of 2310 in DR4 mice immunized with these MODs (Fig. 5D).
We conclude that modified sequences 2191-M2, 2271-M3, 2231-M1 and 2310-M2
successfully disrupt the ability of the peptides to bind to HLA molecules, thus leading to
diminished T cell recognition. Where single and double amino acid substitutions were made,
the double modifications were more likely to reduce antigenicity and immunogenicity. This
stepwise approach to de-immunization of C2 resulted in the selection of peptides with
diminished antigenicity and immunogenicity. As illustrated here, de-immunization involves
1) immunoinformatics, 2) in vitro validation of computational predictions using HLA
binding assays and 3) in vivo validation studies that measure the impact of epitope
modifications on antigenicity and immunogenicity. The approach may be useful to guide
design of improved recombinant FVIII that elicits lower levels of FVIII neutralizing
antibodies.
4. Discussion
The formation of anti-FVIII antibodies, also known as inhibitors, is a major obstacle to
FVIII gene replacement therapy in hemophilia A patients. After intravenous administration
of FVIII, the immune response mounted is dependent on CD4+ T helper cells, as has been
demonstrated by numerous studies in mice and humans [8–14]. The essential role of CD4+ T
cells in FVIII inhibitor development was confirmed in the case of hemophiliacs infected
with HIV-1. Their inhibitor titers decreased as CD4+ T cells declined in the course of HIV
disease, and returned when CD4 T cells were normalized following HIV treatment [13, 48].
Further evidence for the importance of CD4+ T help for the development inhibitory
antibodies cells is the observation of somatic hypermutation, a known T cell dependent
process [49–51]. More recently, interference with T-B cell interactions in hemophilic mice
was shown to reduce inhibitor formation [10, 13].
If CD4 T cells play a central role in the development of inhibitors, then T cell epitopes are
the key to reducing immunogenicity. T cell epitopes are peptides generated from exogenous
antigens that bind to MHCII of antigen presenting cells (APC). Determination of
immunodominant T cell epitopes is an important step in designing less immunogenic
biotherapeutics, such as a de-immunized version of human FVIII [15, 18–20]. In this study,
we demonstrated that immunogenic peptides in the C2 domain of FVIII could be modified
to reduce MHCII binding and that these modified peptides also display reduced antigenicity
in a hemophilic E16 mouse model (H-2b) and HLA-DR transgenic mice.
In the present study, we measured predicted epitope immunogenicity in two distinct mouse
models that differ in FVIII and class II MHC expression: (i) a FVIII knockout mouse (E16)
that expresses no C2 domain at any point in development and normally expresses mouse
class II MHC and (ii) HLA DR transgenic models, which express whole FVIII protein
throughout development, a single human class II MHC allele and no mouse class II MHC.
The immunogenicity study results, in which mice were immunized with C2 domain ORG
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sequences, are consistent with predicted responses for the two different phenotypes in terms
of epitope recognition. A genetic cross of the two mouse models, E16xDR3 mice, exhibited
an intermediate immune response, as expected of mice that have endogenous FVIII and both
mouse and human MHC.
To be specific, 2191-O immunogenicity in E16 mice is consistent with the absence of
tolerance induction to this sequence (the mice do not have FVIII) and the presence of MHC
(I-Ab) motifs in the sequence (Table 2). The lack of immunogenicity observed for the other
ORG peptides, despite an expected lack of tolerance induction to these sequences as well,
may be explained by the absence of I-Ab MHC binding motifs in their sequences, with the
exception of 2231-O, which does have I-Ab motifs. 2231-O may not be immunogenic for
other reasons, such as peptide processing.
With regard to the HLA DR transgenic models, peptides predicted to be HLA ligands were
immunogenic when the sequence contained mismatches between the human FVIII sequence
used in the immunization and the corresponding sequence in the native mouse FVIII protein
(Table 2). To be immunogenic, the mismatches had to occur within 9-mer sequences that
also contained HLA DR3 or DR4 binding motifs. As these 9-mers could be presented to the
mouse T cell and would be ‘foreign’ to the mouse, they stimulate T cell proliferation.
Peptides that were predicted to bind HLA DR3 and/or DR4 but did not stimulate immune
responses were found to contain no mouse/human sequence mismatches. As these sequences
do not appear ‘foreign’ to the mouse, no immune response is expected because tolerance
induction mechanisms either limited or eliminated auto-reactive T cells. Notably,
immunization with complete Freund’s adjuvant did not break tolerance, but was sufficient to
tip the regulatory and effector T cell population balance in favor of proliferation only in
response to the ‘foreign’ sequences.
Following selection of immunogenic ORG peptides in the E16 and DR transgenic mouse
models, we set out to determine to what degree modification of these peptides would reduce
their immune potential in terms of both antigenicity and de novo immunogenicity. In
proliferation assays, MOD peptides were less antigenic than ORG peptides (Figure 4). The
only exception to this finding was 2191-M1, which exhibited immunogenic properties
similar to the parent ORG across a ten-fold range of peptide concentrations. In general,
lower antigenicity was observed for those peptides that had two, rather than just one amino
acid substitution. For example, in DR3×E16 mice, T cells showed the lowest responses to
2191-M2 and 2271-M3; in DR4 mice, T cells showed the lowest responses to 2231-M1,
2231-M2 and 2310-M2. With the exception of 2231-M1, these MODs have two or more
amino acids substitutions; where only a single residue was mutated, the reduction in
proliferative response was less pronounced. Similarly in terms of de novo immunogenicity,
in general, the more mutations, the lower the observed proliferative response. While
proliferative responses to 2191-M1 and 2271-M1 in DR3×E16 mice and 2231-M2 and
2310-M3 in DR4 mice were observed, 2191-M2, 2271-M3, 2231-M1 and 2310-M2 were
significantly lower.
Despite the link between the number of mutations and decreased proliferation, the de-
immunization process cannot be simply reduced to an accumulation of random mutations
that would eventually abrogate HLA binding and reduce immunogenicity. Rather, it is a
process that involves minimizing the number of targeted substitutions that will broadly
minimize immunogenicity across genetically diverse HLA types while also minimizing their
impact on bioactivity. Taken together, the data suggest that multiple and carefully selected
amino acid substitutions were advantageous to disruption of HLA binding and reduction of
immunogenicity, and thus, multiple, select modifications may contribute to better de-
immunization of the C2 domain. We estimate that as few as one or two amino acid changes
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in a single immunodominant epitope in the C2 domain could be sufficient to lower the
immunogenicity threshold enough to render a C2 domain protein non-immunogenic.
However, it is likely that additional modifications would be required not only in C2 but also
in other domains to fully de-immunize whole FVIII. Given that sequence modifications may
also impact protein structure and/or function, it would be optimal to minimize the number of
deimmunizing mutations to avoid detrimental effects on structural and/or functional
integrity. Future studies using intact C2 domain and whole FVIII will address the critical
balance between these competing factors that influence clinical success.
In summary, we identified immunodominant T cell epitopes in the C2 domain of FVIII and
developed de-immunized versions by targeted sequence modification. We synthesized
original and modified peptides to evaluate their abilities to stimulate HLA-restricted T cells.
We found that while 2271-O was reactive in DR3 transgenic mice, 2231-O and 2310-O
responses were mainly observed in DR4 mice. Peptide 2191-O was apparently H-2b-
restricted, in that it caused T cell proliferation only in E16 and E16xDR3 mice. We also
found that the MODs 2191-M2, 2231-M1, 2271-M2 and 2310-M2 showed lower HLA
binding and proliferation responses compared with their respective ORGs. Although most
modifications resulted in reduced immunogenicity, some modifications remained partially
immunogenic.
This stepwise approach to reducing biotherapeutic immunogenicity promises to advance the
design and production of a modified, yet functional, recombinant FVIII protein. It is
anticipated that a T-cell epitope-modified FVIII would be useful for the treatment of existing
and new hemophilia A patients. New patients would not develop T cells that are required for
FVIII inhibitor production in the absence of immunogenic T-cell epitopes. Reduced FVIII-
specific T cell activation in existing patients would prevent inhibitor production, too, as the
association of T cells and inhibitor development in the case of HIV-infected hemophiliacs
suggests: as CD4+ T cells decline in the course of disease, so do FVIII inhibitors; restoration
of T cell function by treatment with antiretroviral therapy results in the return of inhibitors to
previous levels [13,42]. Finally, the de-immunization approach applied to FVIII will serve
as a guide for improvement of other immunogenic biologics.
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Highlights
• Resistance to Factor VIII therapy for hemophiliacs is attributed to
immunogenicity.
• We use a systematic approach to reduce immunogenicity by epitope
modification.
• Immunoinformatic tools find FVIII T-cell epitopes and de-immunizing
modifications.
• Pinpoint mutations reduce FVIII epitope immunogenicity in transgenic mouse
models.
• De-immunization can be broadly applied to lower the risk of immunogenic
biologics.
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Fig. 1. HLA Class II epitope map of the FVIII C2 domain as predicted by EpiMatrix
EpiMatrix-predicted 9-mer hits for 8 prevalent HLA class II alleles are aligned along the
human FVIII C2 sequence. Any peptide scoring above 1.64 on the EpiMatrix ‘Z’ scale (top
5%) is considered to be a potential epitope (gray bars). Peptides scoring above 2.32 on the
scale (top 1%) are extremely likely to bind MHC (black bars). Published epitopes
determined by experimental methods are similarly aligned (blue bars). EpiMatrix identified
clusters of epitopes spanning residues 2191–2210, 2231–51, 2254–69, 2271–89, 2299–2317
and 2310–30 that are framed in blue. The EpiMatrix algorithm finely maps the positions of
published epitopes.
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Fig. 2. Direct binding of C2 peptides to HLA alleles
In 96-well plates, non-biotinylated test peptide at a concentration of 100 μM competes for
binding to purified Class II molecules (50 nM). Blue bar is average across alleles. Dots
represent percent inhibition of binding to HLA alleles: DRB1*0101, DRB1*0301,
DRB1*0401, DRB1*0701 and DRB1*1501. The amino acid modifications were made to
prevent binding across all HLA DR alleles; however, the predicted changes were not always
universal and therefore some peptides could be expected to demonstrate residual binding to
selected MHC.
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Fig. 3. De novo immunogenicity of C2 peptides in hemophilic and HLA DR transgenic mice
Six ORG peptides (2191-O, 2231-O, 2254-O, 2271-O, 2299-O, and 2310-O) were tested for
their ability to stimulate T cells proliferation in different mouse strains: (A) E16, (B) DR3,
(C) DR3×E16, and (D) DR4. Mice were immunized with mixed 6 ORG peptides (3 μg
each), emulsified in CFA. After two weeks, T cell proliferation was determined using
pooled lymph nodes (LN) cells from each mouse strain (n=2). Cells were primed with
indicated ORG peptides at concentrations of 0, 1, 3 and 10 μg/ml. Values are means ± SEM
of triplicate cultures, p < 0.05.
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Fig. 4. Epitope modification of immunodominant C2 peptides lowers immune recall responses to
original sequences
Corresponding HLA dominant peptides and their modifications were tested for their ability
to lower antigenicity of protein in DR3×E16 and DR4 mice. A: DR3×E16 mice were
immunized with 2191-O. B: DR3×E16 mice were immunized with 2271-O; C: DR4 mice
were immunized with 2231-O. D: DR4 mice were immunized with 2310-O. 3 μg of each
peptide was emulsified in CFA. Subcutaneous injection was given to mice via a hind
footpad and the base of tail. Two weeks later, T cell proliferation was determined using
pooled LN cells from immunized mice (n=2). Cells were primed with indicated ORG and
MOD peptides at concentrations of 0, 1, 3 and 10 μg/ml. Values are means ± SEM of
triplicate cultures, p < 0.05.
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Fig. 5. Epitope modification of immunodominant C2 peptides reduces de novo immunogenicity
Corresponding HLA dominant peptides and their modifications were tested for their ability
to lower immunogenicity of protein in DR3×E16 and DR4 mice. A: DR3×E16 mice were
immunized with a mixture of 2191-M1 and 2191-M2; B: DR3×E16 mice were immunized
with a mixture of 2271-M1, 2271-M2 and 2271-M3; C: DR4 mice were immunized with a
mixture of 2231-M1, 2231-M2 and 2231-M3; D: DR4 mice were immunized with a mixture
of 2310-M1, 2310-M2 and 2310-M3. 3 μg of each peptide was emulsified in CFA.
Subcutaneous injection was given to mice via a hind footpad and the base of tail. Two weeks
later, T cell proliferation was determined using pooled LN cells from immunized mice
(N=2). Cells were primed with indicated ORG and MOD peptides at concentrations of 0, 1,
3 and 10 μg/ml. Values are means ± SEM of triplicate cultures, p < 0.05.
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Table 1
FVIII C2 domain epitope sequences and modifications
An EpiMatrix analysis of the FVIII C2 domain was performed to computationally map T-cell epitopes that
may contribute to FVIII immunogenicity. OptiMatrix, an algorithm that identifies amino acids that contribute
to HLA binding and creates mutants that reduce predicted HLA affinity, was used to identify modified FVIII
C2 sequences that may lower FVIII immunogenicity. Original sequences are indicated by ORG; modified by
MOD. Boxed amino acids contribute significantly to HLA binding and are considered optimal sites for amino
acid substitution. De-immunization was performed by replacing these residues with those predicted to disrupt
binding to HLA.
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Table 2
Impact of FVIII C2 domain species-specific sequences on epitope immunogenicity
Mouse and human FVIII sequences were aligned using ClustalW (SwissProt Accession Q06194 and P00451,
respectively). EpiMatrix-predicted epitope cluster sequences in the human C2 domain are shown aligned with
the corresponding mouse sequences and EpiMatrix hits for the MHC alleles tested in mice. Human sequence
mismatches are colored red, DR3 hits as black bars, DR4 as gray and I-Ab as white. Epitope cluster
immunogenicity is observed in HLA DR mice, which produce mouse FVIII, where non-conservative
mismatches overlap with EpiMatrix hits. Figure 3 illustrates C2 ORG epitope immunogenicity.
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